The hypocholesterolemic effects of Kluyveromyces marxianus YIT 8292 crude cell wall (KM-CW) were examined. In pilot studies, KM-CW tablets were administered to mildly hypercholesterolemic subjects at doses of 8.0, 4.0, 2.0, or 1.0 g/d for 4 weeks. Total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) decreased at doses above 2.0 and 4.0 g/d, respectively. Further, we examined the effect of intake of yogurt containing 3.0 or 4.0 g of KM-CW/d for 8 weeks in normal and hypercholesterolemic subjects in a double-blind placebo-controlled study. The intake of either of the KM-CW-containing yogurts was associated with significantly improved TC and LDL-C in hypercholesterolemic subjects, but had no effect on these levels in normal subjects. TC was significantly lower at week 8 in the hypercholesterolemic subjects who ingested yogurt containing 3.0 or 4.0 g of KM-CW than in those who consumed placebo yogurt. Intake of KM-CW might contribute to the prevention of hypercholesterolemia.
Since the pioneering results of the Framingham study 1) were disclosed, hypercholesterolemia has been recognized as a major risk factor for the development of coronary heart disease. 2, 3) Lowering plasma cholesterol levels has been proven to reduce mortality from myocardial infarction, 4) hence the search for natural substances capable of lowering plasma cholesterol is ongoing in the fields of nutrition and medicine.
Kluyveromyces marxianus is a homothallic hemiascomycetous species usually found in kefir grains, cheese, and other dairy products. 5) Belem and Lee have outlined the following advantages of K. marxianus as a food material: 5) (i) it shows good growth yield, which is important for cost efficiency in the food industry; (ii) it is accepted as a safe microorganism; (iii) it is a lactosefermenting yeast that can grow on whey waste; (iv) it is the only yeast permitted to be grown on whey in the USA. We reported in a previous study that of the 81 yeast strains used in the food industry, K. marxianus YIT 8292 whole cells exhibited the most potent hypocholesterolemic activity in rats fed a high-cholesterol diet, 6) and we have found that cell wall polysaccharides were the major active components of K. marxianus YIT 8292. 7) In rats, feeding cell wall polysaccharide-enriched fractions (crude cell wall and cell wall fractions) resulted in increased fecal sterol excretion and cecal concentration of short-chain fatty acids (SCFA). 7) Therefore, the cell wall polysaccharides of K. marxianus YIT 8292 can exert hypocholesterolemic activity through the suppression of intestinal cholesterol absorption, the interruption of the enterohepatic circulation of bile acids, and/or the production of SCFA.
The vast majority of the cell wall polysaccharides of K. marxianus YIT 8292 are insoluble dietary fiber. 7) Soluble dietary fiber has been found to reduce serum cholesterol levels in various studies, but there have been few reports on the hypocholesterolemic effects of insoluble dietary fiber in humans. 8) In the present study, we performed three experiments to examine the hypocholesterolemic effect of K. marxianus YIT 8292 crude cell wall (KM-CW) in humans. In two pilot studies, KM-CW was administered as tablets to adults with total cholesterol above 200 mg/dl at doses of 8.0 or 4.0 g/d (study 1), or 2.0 or 1.0 g/d (study 2) for 4 weeks. On the basis of those studies, the effect of intake of yogurt containing 3.0 or 4.0 g of KM-CW for 8 weeks was examined in 48 normal and hypercholesterolemic adults in a double-blind placebo-controlled study (study 3).
Materials and Methods
Preparation of KM-CW. K. marxianus YIT 8292 was aerobically cultured for 24 h, as described previously.
7)
The living cells were suspended in pure water and autoclaved at 121 C for 15 min. The suspension was then centrifuged to separate the supernatant and the residue containing the cell walls. This residue was washed with pure water, and the fraction was used as KM-CW. The nutritional composition of KM-CW is shown in Table 1 .
Test samples. The composition of the tablet for study 1 (T1) was as follows (g/100 g): KM-CW, 72.0; cellulose powder, 15.0; powdered sugar, 10.0; tricalcium phosphate, 2.5; magnesium stearate, 0.5. Tablets were made by the direct powder-compression method with an eccentric tablet press (weight, 370:4 AE 4:3 mg/tablet). In study 2, two different kinds of tablets (T2a and T2b) were used. The composition of T2a was the same as T1. The composition of T2b was as follows (g/100 g): KM-CW, 36.0; cellulose powder, 31.3; powdered sugar, 15.9; casein, 13.8; tricalcium phosphate, 2.5; magnesium stearate, 0.5. Tablets 2a and 2b were compressed with an eccentric tablet press (weight, 308:6 AE 3:4 mg/ tablet). These tablets were put into a nylon bag and sealed with a vacuum sealer.
Three different kinds of yogurt were used in study 3. These yogurts were produced from a mixture of skim milk and whole milk powder that had been fermented using starters, Lactobacillus casei Shirota and Streptococcus thermophilus YIT 2001, with added sweeteners and polysaccharide thickeners. KM-CW was added to the yogurt at a concentration of 3.0 or 4.0 g/90 g. Placebo yogurt was prepared by adding water instead of KM-CW. All the yogurts had the same composition, except for KM-CW.
Freshly prepared yogurts were dispensed into cups (90 g/cup), packaged, and stored at 4 C prior to delivery to subjects.
Subjects. The subjects were recruited from employees of the Yakult Central Institute for Microbiological Research. The two pilot studies, study 1 and study 2, included 31 and 20 adults respectively, with total cholesterol levels above 200 mg/dl. Study 3 involved 48 normal adults and hypercholesterolemic adults with total cholesterol levels of 150 to 310 mg/dl. Those taking cholesterol-lowering medication were excluded from the studies. All subjects gave informed consent to a protocol approved by the Human Research Ethics Committee of the Yakult Central Institute.
Study-1 and study-2 subjects were divided into two experimental groups. Study-3 subjects were divided into three experimental groups. Although three study-3 subjects (one placebo subject, and two from the 3.0 g/d KM-CW group) withdrew during the yogurt-intake period because of gastrointestinal problems (nausea in two subjects, and mild diarrhea in the third), there were no withdrawals in study 1 or study 2. There was no correlation between the withdrawal rate and the dosage of KM-CW in study-3 subjects, hence the withdrawals were not thought to be associated with intake of the testsamples.
The initial characteristics of subjects that completed the studies are shown in Table 2 . There were no significant differences in the initial characteristics between the groups in each study.
Study design. In the pilot studies, the effects of the two different doses of KM-CW (study 1, 8.0 and 4.0 g/d; study 2, 2.0 and 1.0 g/d) on serum lipids over a 4-week period were compared. In study 1, subjects were randomly allocated to one of two groups, receiving either 5 or 10 T1 tablets three times a day, after meals. In study 2, subjects were divided into two groups, and received 3 T2a or T2b tablets three times a day, after meals. Blood was collected from each subject before and after the intake period. Study 3 was a double-blind, randomized, placebocontrolled parallel study comparing the effects on serum lipids of yogurts containing 3.0 or 4.0 g of KM-CW with a placebo yogurt not containing KM-CW. This study consisted of an 8-week sample feeding period and a 4-week post-feeding period. Subjects were randomly allocated to one of three groups, receiving one of the three different yogurts once daily. Blood was collected from each subject at week 0, 4, 8, and 12.
Blood assay. Blood was drawn in the early morning after overnight fasting (10 h). The serum lipids, apolipoproteins, blood cells, and biological examinations were analyzed at Japan Nova Medical Laboratory (Tokyo) and at Showa Medical Science (Tokyo).
Statistical analysis. All statistical analyses were performed with the SAS system for Windows (release 6.12; SAS Institute, Cary, NC). The results are given as means AE SD. The paired t-test was used to analyze changes between the post-intake and baseline levels. Dunnett's test was used to compare differences between groups in study 3. Differences in serum lipid and apolipoprotein levels from baseline to week 4, 8, or 12 in study 3 were analyzed using repeated-measure models based on a mixed model with the restricted maximum likelihood method with Dunnett's test. Statistical significance was established at p < 0:05.
Results

Pilot studies
In the pilot studies, mildly hypercholesterolemic subjects with total cholesterol levels above 200 mg/dl, randomly allocated to one of two groups, received KM-CW for 4 weeks at one of two doses (study 1, 8.0 and 4.0 g/d; study 2, 2.0 and 1.0 g/d). The serum lipid levels at the start and end of the intake period in each group are shown in Table 3 . Serum total cholesterol and LDLcholesterol levels decreased significantly with intake of 4.0 and 8.0 g/d KM-CW for 4 weeks. In the 2.0-g/d KM-CW group, the level of total cholesterol, but not that of LDL-cholesterol, decreased significantly from the initial level after the intake period. HDL-cholesterol and triglyceride levels did not change significantly in any of the groups. Double-blind, randomized placebo-controlled parallel study
The effect of yogurts containing 3.0 or 4.0 g of KM-CW on serum lipids in normal subjects and hypercholesterolemic subjects was examined in a doubleblind, randomized, placebo-controlled parallel study. The changes in serum lipid levels are shown in Table 4 . Total cholesterol decreased significantly from initial levels after 4 weeks in the 4.0-g/d KM-CW group. Mean LDL-cholesterol decreased significantly from initial levels after 8 weeks in the 3.0-g/d KM-CW group, and after both 4 and 8 weeks in the 4.0-g/d KM-CW group. The results of stratified analysis are shown in Tables 5  and 6 . Total cholesterol and LDL-cholesterol levels in normal subjects with total cholesterol under 220 mg/dl did not change significantly from initial levels in any group, whereas those of hypercholesterolemic subjects with total cholesterol above 220 mg/dl decreased significantly at week 4 or 8 in both groups that consumed yogurts containing KM-CW. Total cholesterol levels at the end of the intake period were significantly lower in hypercholesterolemic subjects who consumed either of the KM-CW yogurts than in those who consumed the placebo yogurt.
Apo-B levels in both normal and hypercholesterolemic subjects decreased significantly during the intake period in all treatment groups. Apo-AI levels in hypercholesterolemic subjects decreased significantly at week 4 in the placebo group, but did not change during the intake period in the 3.0-or the 4.0-g/d KM-CW group.
The results of hematological and biological tests are shown in Table 7 . GOT, GPT, and -GTP levels in the 4.0-g/d KM-CW group decreased significantly from initial levels at the end of the intake period. GPT and urea-nitrogen levels and white blood cell counts all changed significantly following intake of yogurts containing 3.0 g of KM-CW. Changes in those values of all subjects were within the normal range. No significant differences were found between the groups.
Discussion
Elevated serum total cholesterol is associated with increased risk of coronary artery disease.
3) A reduction in dietary saturated fat and cholesterol is the main treatment for patients with hypercholesterolemia. 9) However, there is substantial evidence that soluble dietary fiber such as that from oats and psyllium favorably affects serum lipid profiles.
8) It is generally recognized that soluble dietary fiber exerts a potent cholesterol-lowering effect, whereas insoluble dietary fiber does not exhibit a significant cholesterol-lowering effect. 8) We have reported that cell wall polysaccharides of K. marxianus YIT 8292 are insoluble dietary fibers, but that they exert a potent cholesterol-lowering effect in rats fed a high-cholesterol diet.
7) The present studies show that intake of a cell wall polysaccharide-enriched fraction of K. marxianus YIT 8292 (KM-CW) decreased total cholesterol and LDL-cholesterol levels in hypercholesterolemic subjects (Tables 3 and 6 ). Soluble dietary fiber is viscous and produces gel-like lumps in an aqueous solution at a low concentration, and therefore its application is limited to particular food products such as jelly. Cell wall polysaccharides from K. marxianus YIT 8292 are of low viscosity and are non-gelling because of their water-insolubility. These characteristics of cell wall polysaccharides can confer advantages as a food material.
In pilot studies to narrow the range of effective doses of KM-CW, both serum total cholesterol and LDLcholesterol levels in mildly hypercholesterolemic subjects decreased at doses above 4.0 g/d (Table 3 ). An intake of 2.0 g/d of KM-CW decreased serum total cholesterol, but not LDL-cholesterol. These results suggest that the minimum effective dose of KM-CW for lowering of serum total cholesterol or LDLcholesterol might be around 2 or 4 g/d respectively. We further examined the effects of yogurts containing 3.0 or 4.0 g of KM-CW on serum lipid levels in normal subjects and hypercholesterolemic subjects. Intake of either of the yogurts containing KM-CW decreased total cholesterol and LDL-cholesterol levels in hypercholesterolemic subjects, but did not change these levels in normal subjects (Tables 5 and 6 ). Total cholesterol levels at the end of the intake period were significantly lower in hypercholesterolemic subjects who consumed yogurt supplemented with 3.0 or 4.0 g of KM-CW than in those who consumed placebo-yogurt (Table 6 ). These results show that KM-CW exerted a cholesterol-lowering effect in hypercholesterolemic subjects at a similar dosage to that for soluble dietary fibers such as pectin and guar gum.
Some reports [10] [11] [12] have shown that dietary supplementation with brewer's yeast decreases serum total cholesterol in humans, but other studies [13] [14] [15] [16] have failed to show such a beneficial effect. Nicolosi et al. reported that daily intake of 15 g of -glucan derived from baker's yeast improved plasma cholesterol levels in hypercholesterolemic men. 17) Nakamura et al. reported that daily intake of 6 g of cell wall polysaccharides, highly purified from brewer's yeast, decreased serum total cholesterol in hypercholesterolemic subjects.
18) The effective doses of KM-CW in humans were lower than those of materials derived from baker's yeast or brewer's yeast. We found in a previous study that the hypocholesterolemic activity of yeasts varied markedly between species and strains, and that strains of K. marxianus, especially K. marxianus YIT 8292, exhibited more potent hypocholesterolemic activity than other yeasts containing baker's yeast or brewer's yeast. 6) Nguyen et al. reported that the composition of cell wall polysaccharides varied with species and strain.
19) The differences in hypocholesterolemic activity between those yeasts might reflect compositional differences in cell wall polysaccharides.
Although there have been inconsistent reports, several studies suggest that yogurt has a moderate cholesterol- lowering effect. 20) In the present study, the mean value of LDL-cholesterol in hypercholesterolemic subjects decreased slightly with intake of placebo yogurt, although this was not significant (Table 6 ). The mean decrease in LDL-cholesterol concentration was more marked in hypercholesterolemic subjects who consumed yogurt supplemented with 4.0 g of KM-CW than in those who consumed KM-CW tablets at doses of 4.0 g/d (Tables 3 and 6 ). Therefore, there is a possibility that the additive or synergetic effect of KM-CW and yogurt resulted in the marked reduction in LDL-cholesterol. Further study is needed to examine this possibility.
In conclusion, the results of the present studies show that intake of KM-CW decreased serum total cholesterol and LDL-cholesterol levels in hypercholesterolemic subjects. Therefore, K. marxianus YIT 8292 might be useful as a new source of dietary fiber.
